Tim Grob

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

MDS/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities.

MDS/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities.

Journal: Blood advances
Published: September 11, 2025

MDS/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities.

MDS/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities.

Journal: Blood advances
Published: September 11, 2025

MDS/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities.

MDS/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities.

Journal: Blood advances
Published: September 11, 2025

MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia.

MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia.

Journal: Blood
Published: February 21, 2025

Double mutant DNMT3A AML: a unique subtype experiencing increased DNA damage and poor prognosis.

Double mutant DNMT3A AML: a unique subtype experiencing increased DNA damage and poor prognosis.

Journal: Blood advances
Published: September 03, 2024

Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML.

Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML.

Journal: Blood advances
Published: August 12, 2024

Prognostic relevance of molecular measurable residual disease detection in AML with mutated CEBPA.

Prognostic relevance of molecular measurable residual disease detection in AML with mutated CEBPA.

Journal: HemaSphere
Published: March 20, 2024

Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia.

Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 31, 2022

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome.

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome.

Journal: Blood
Published: October 18, 2021

FLT3-ITD mutations in acute myeloid leukaemia - molecular characteristics, distribution and numerical variation.

FLT3-ITD mutations in acute myeloid leukaemia - molecular characteristics, distribution and numerical variation.

Journal: Molecular oncology
Published: January 15, 2021

Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis.

Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis.

Journal: Molecular oncology
Published: December 18, 2020

Selective Requirement of MYB for Oncogenic Hyperactivation of a Translocated Enhancer in Leukemia.

Selective Requirement of MYB for Oncogenic Hyperactivation of a Translocated Enhancer in Leukemia.

Journal: Cancer discovery
Published: December 15, 2020
Showing 1-12 of 20

Last Updated: 09/26/2026